Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 93
Inquire Before Buying

Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. Cancer anorexia or cachexia often is associated with weakness, fatigue, and a poor quality of life. This symptom of anorexia not only affects the patient but also frequently has an impact on family members, as the patient is no longer able to participate fully in eating as a social activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).

- The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Anorexia-Cachexia Syndrome - Overview
Cancer Anorexia-Cachexia Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development
Abreos Biosciences Inc
Acacia Pharma Ltd
Aeterna Zentaris Inc
Incyte Corp
Lakewood-Amedex Inc
Novartis AG
Paradigm Biopharmaceuticals Ltd
RaQualia Pharma Inc
Viking Therapeutics Inc
Zeria Pharmaceutical Co Ltd
Cancer Anorexia-Cachexia Syndrome - Drug Profiles
(formoterol fumarate + megestrol acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-380 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1889 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-706 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Foxo1-nRNA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-1510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-1940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TCMCB-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cancer Anorexia-Cachexia Syndrome - Dormant Projects
Cancer Anorexia-Cachexia Syndrome - Discontinued Products
Cancer Anorexia-Cachexia Syndrome - Product Development Milestones
Featured News & Press Releases
May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Cachexia - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 42
    Cachexia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cachexia - Pipeline Review, H2 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape. Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis, HIV, cancer, and in individuals with age-associated „failure to th......
  • Ependymoma - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 131
    Ependymoma - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H2 2017, provides an overview of the Ependymoma (Oncology) pipeline landscape. Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebel......
  • Thyroid Cancer - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 490
    Thyroid Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H2 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape. Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. ......
  • Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 39
    Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides an overview of the Hepatic - Colorectal Metastasis (Oncology) pipeline landscape. Patients who present with hepatic colorectal metastases are usually asymptomatic. Symptoms such as abdominal pain and weight loss are associated with advan......
  • Hypopharyngeal Cancer - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 124
    Hypopharyngeal Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2017, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape. Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophy......
  • Malignant Mesothelioma - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 547
    Malignant Mesothelioma - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape. Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubr......
  • Malignant Pleural Effusion - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 32
    Malignant Pleural Effusion - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2017, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape. Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside o......
  • Global Breast Cancer Monoclonal Antibodies Market Professional Survey Report 2017
    Published: 04-Sep-2017        Price: US 3500 Onwards        Pages: 123
    This report studies Breast Cancer Monoclonal Antibodies in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - F. Hoffmann-La Roche - Amgen - Mylan - Pfizer......
  • Global Mucositis Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Mucositis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs